Farmanews.com

Notas de Prensa  

17 de mayo de 2005

Amgen Names Jim Daly, Senior Vice President, North America Commercial Operations

THOUSAND OAKS, Calif., May 17, 2005 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN), the world´s largest biotechnology company, today announced the appointment of Jim Daly to the new position of senior vice president, North America Commercial Operations. Daly, formerly vice president and general manager of the U.S. Oncology Business Unit at Amgen, will be responsible for leading the company´s commercial activities in the United States and Canada. Daly will report to George Morrow, executive vice president, Global Commercial Operations.

"The newly formed North America Commercial Operations organization, with Jim at the head, will provide better coordination and integration across Amgen´s United States and Canada commercial operations as we prepare to launch new therapies emerging from our product pipeline," said Morrow. "Jim brings 20 years of extensive sales, marketing and general management leadership experience to this new position and I anticipate great success for this important part of our business under Jim´s guidance."

Daly joined Amgen in early 2002 as vice president and general manager, U.S. Oncology Business Unit. In this role, Daly led the successful launches of Aranesp(R) (darbepoetin alfa), Neulasta(R) (pegfilgrastim) and Kepivance(TM) (palifermin), and was instrumental in establishing their strong market positions. Prior to joining Amgen, Daly spent 17 years at Glaxo Wellcome/GlaxoSmithKline (GSK), where he progressed through positions of increasing responsibility in marketing, including his role as vice president and general manager, Respiratory and Anti-Infectives Business Division at GSK.

Daly received his undergraduate degree in Pharmacy and his master´s degree in Business Administration from the State University of New York in Buffalo.

About Amgen

Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.

SOURCE: Amgen

Amgen, Thousand Oaks Christine Cassiano, 805-447-4587 (media) Arvind Sood, 805-447-1060 (investors)

Subir  

Subir notas de prensa y convocatorias

Próximas convocatorias   

No hay próximas convocatorias
Ver todas

Especialidades  

Busca notas de prensa por especialidad médica o enfermedad.



Ver todas

Archivo  

Busca notas de prensa por su fecha de edición.

  Selecciona el año


Copyright © 2017, Farmavet, S.L. Todos los derechos reservados.